Shani Alexander

23 hours ago | bioworld.com | Shani Alexander

Baxter brings room temperature surgical patch to EuropeBaxter International Inc. recently launched in Europe a new version of its surgical patch, the Hemopatch Sealing Hemostat, which can be stored at room temperature. The improved Hemopatch device eliminates the need for refrigeration, allowing surgeons to have the product on hand to quickly control bleeding or prevent leakage during surgery. BioWorld MedTech

6 days ago | bioworld.com | Shani Alexander

Predict4Health rebrands as Okeiro, raises €10M for transplantation predictive toolFrench startup Predict4Health SAS rebranded to Okeiro and raised €10 million (US$11.35 million). The series A funding round was led by Alven, Forepont Capital Partners and Red River West. Funds will be used to accelerate the deployment of the company’s AI-based technology which prevents organ failure. BioWorld MedTech Financings Urology Artificial intelligence Europe

6 days ago | bioworld.com | Shani Alexander

Neuranics raises $8M for magnetic sensing technologyNeuranics Ltd. recently raised $8 million in seed funding which is “extremely important” for the company as it looks to scale its magnetic sensing technology, which detects muscle activity without touching the skin, Noel McKenna, CEO told BioWorld. “The funds will help accelerate our go to market strategy and advance our R&D roadmap,” he said. BioWorld MedTech Financings Seed Diagnostics Wearable Europe

1 week ago | bioworld.com | Shani Alexander

Cardiovia Viaone epicardial access system secures US FDA clearanceCardiovia Ltd.' Viaone epicardial access system received U.S. FDA clearance for treating cardiac arrhythmias. The device provides clinicians with a safe and minimally invasive technology to reach the heart’s outer surface, known as the pericardial space, without the need for a sharp needle, which can cause perforation. BioWorld MedTech Regulatory Cardiovascular U.S. 510(k) FDA

1 week ago | bioworld.com | Shani Alexander

Saliva test predicts prostate cancer better than PSA U.K. scientists developed a saliva-based test which better predicts the risk of prostate cancer than current prostate-specific antigen (PSA) blood tests by analyzing DNA to look for genetic variants linked to prostate cancer and calculating a polygenic risk score. BioWorld MedTech Clinical Cancer Oncology Europe